SAN DIEGO, Nov. 10, 2004 (PRIMEZONE) -- NatureWell, Inc. (OTCBB:NAWL) is pleased to announce that the Company's President & CEO, Jim Arabia, is featured in an interview by WallSt.net. The interview covers the company's unique proprietary healthcare products, including their signature migraine relief product, MigraSpray. The growth potential of MigraSpray sales and other upcoming products was highlighted. The interview also featured Mr. Arabia's personal insights into the company's philosophy and potential. To hear the entire interview, visit www.wallst.net. The interview can be accessed either by locating the ticker symbol (NAWL) on the left hand column under the appropriate exchange, or by entering the company's trading symbol (NAWL) in the Audio Search window.
Most noted during the interview was the news that NatureWell's goal for the upcoming calendar year is a campaign to target their products to healthcare practitioners who, in turn, market to their patients from their practices. The company estimates that over 100,000 professionals fit this target demographic.
NatureWell, Inc. (www.naturewell.com) is engaged primarily in the research and development of proprietary healthcare products intended for a variety of conditions and has completed development of a homeopathic over-the-counter (OTC) drug used for the treatment and prevention of migraine headaches. For more information please call 619-234-0222 or email corporate@naturewell.com.
The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking statements made on behalf of the company. All such forward-looking statements are, by necessity, only estimates of future results and actual results achieved by NatureWell may differ materially from these statements due to a number of factors. NatureWell assumes no obligations to update these forward-looking statements to reflect actual results, changes in assumptions or changes in other factors affecting such statements. Investors and potential investors should independently investigate and fully understand all risks before making investment decisions.